Saccade characteristics of controls and patients with schizophrenia*
| Group; mean ± SD | Patient subgroup; mean ± SD | ||||
|---|---|---|---|---|---|
| Characteristic | Controls, n = 29 | Schizophrenia, n = 38† | Antipsychoticfree, n = 13 | Clozapine, n = 10 | Haloperidol, n = 15† |
| Peak velocity, º/s | 634.0 ± 82.5 | 602.1 ± 114.1 | 615.3 ± 93.2 | 643.8 ± 86.9 | 562.0 ± 137.7 |
| Duration, ms | 88.2 ± 17.3 | 91.3 ± 18.0 | 91.9 ± 14.2 | 83.9 ± 7.0 | 96.1 ± 24.3 |
| Pregain | 0.93 ± 0.04 | 0.91 ± 0.05 | 0.93 ± 0.06 | 0.91 ± 0.04 | 0.89 ± 0.05 |
| Postgain | 0.75 ± 0.05 | 0.73 ± 0.06 | 0.73 ± 0.06 | 0.76 ± 0.05 | 0.71 ± 0.06 |
SD = standard deviation.
↵* No differences in basic saccade characteristics (peak velocity, duration, gains) were found among any of the groups. Saccade gains (defined as saccade amplitude/target amplitude) were calculated at baseline (pregain) and after saccade adaptation (postgain) and did not differ significantly between controls and patients with schizophrenia (Student t tests) or among patient subgroups (univariate analyses of variance).
↵† Not significant.